Skip to content

Kairos-study: Sleep interventions in night shift workers

Kairos-study: Sleep interventions in night shift workers - Kairos-study

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON53238
Enrollment
90
Registered
2023-04-26
Start date
2023-06-01
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

risicofactoren voor metabole aandoeningen, alertheid Metabolic health Sleep

Interventions

All participants, including those in the control arm, receive advice on general sleep hygiene. In addition, participants in the split sleep intervention receive advice on how to split their daytime

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: • Age 18 to 60 years. • Work at least 3 night shifts a month on average. Night shift defined as work at least 3 hours between 0:00- and 6:00. • Work generally at least 2 night shifts in a row • Work >= 20 hours per week. • History of >= 0.5 year of working night shifts prior to the study. • Expected to remain working night shifts for >= 1 year from inclusion in the study.

Exclusion criteria

Exclusion criteria: • Taking medication that the investigator believes would interfere with the objectives of the study. For example, sleep medication or supplements like melatonin. • Pregnant or having a wish to become pregnant during the study period. • • Using powernaps during, or split-sleep strategies during or prior to, >=50% of the night shifts (prior to the study start).

Design outcomes

Primary

MeasureTime frame
The primary outcomes are the quantity of sleep and alertness during night shifts.

Secondary

MeasureTime frame
Secondary outcomes include quality of sleep, and a set of relevant clinical biomarkers (of metabolic health and anthropometrics). The outcomes will be compared between intervention and control group, pre- and post-intervention.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)